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Background: Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumours in 
the digestive tract. The duodenal GIST (dGIST) is the rarest subtype, representing only 4–5% of all GIST, 
but up to 21% of the resected ones. The diagnostic and therapeutic management of dGIST may be difficult 
due to the rarity of this tumor, its anatomical location, and the clinical behavior that often mimic a variety 
of conditions; moreover, there is lack of consent for their treatment. This study has evaluated the scientific 
literature to provide consensus on the diagnosis of dGIST and to outline possible options for surgical 
treatment.
Methods: An extensive research has been carried out on the electronic databases MEDLINE, Scopus, 
EMBASE and Cochrane to identify all clinical trials that report an event or case series of dGIST. 
Results: Eighty-six studies that met the inclusion criteria were identified with five hundred forty-nine 
patients with dGIST: twenty-seven patients were treated with pancreatoduodenectomy and ninety-six with 
only local resection (segmental/wedge resections); in four hundred twenty-six patients it is not possible 
identify the type of treatment performed (pancreatoduodenectomy or segmental/wedge resections). 
Conclusions: dGISTs are a very rare subset of GISTs. They may be asymptomatic or may involve 
symptoms of upper GI bleeding and abdominal pain at presentation. Because of the misleading clinical 
presentation the differential diagnosis may be difficult. Tumours smaller than 2 cm have a low biological 
aggressiveness and can be followed annually by endoscopic ultrasound. The biggest ones should undergo 
radical surgical resection (R0). In dGIST there is no uniformly adopted surgical strategy because of the low 
incidence, lack of experience, and the complex anatomy of the duodenum. Therefore, individually tailored 
surgical approach is recommended. R0 resection with 1–2 cm clear margin is required. Lymph node dissection 
is not recommended due to the low incidence of lymphatic metastases. Tumor rupture should be avoided.
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Introduction
Gastrointestinal stromal tumours (GIST) are the most 
common type of mesenchymal tumours found in the 
gastrointestinal tract (1). For years, GISTs have been 
defined as smooth gastrointestinal muscle tumors and have 
been called under various names and often misdiagnosed 
as leiomyomas, schwannomas and sarcomas (2). Currently, 
the distinctive feature of GIST is the mutation in the c-kit 
protooncogene leading to gain-of-function and subsequent 
cell proliferation (3-5). GISTs are rare, with relative annual 
incidence of 14.5 per million and prevalence of 129 per 
million (6). GIST may occur anywhere in the digestive tract, 
but are more frequently located in the stomach (60–70%) 
and midgut (25%) and less often in colon and rectum 
(5–10%) (7). Extravisceral GIST occurs in less than 10% of 
patients, most frequently in mesentery, intrabdominal, pelvis 
and retroperitoneal space (7). Duodenal GISTs (dGIST) 
represent only 4–5% of all GISTs, but accounted for 6–21% 
of surgical resected ones (8-10). The complex anatomy of 
the duodeno-pancreatic region can make their diagnosis and 
treatment extremely challenging. Anatomical closeness to 
noble structures (i.e., to the head of the pancreas, kidney and 
biliary structures) can lead to misdiagnosis and inappropriate 
management (11). Additionally, several factors complicate 
the management of dGISTs such as the relative lack of 
experience, the ambiguous clinical manifestations that often 
mimic a wide range of clinical conditions, the anatomical 
complexity and the lack of consensus on treatment. 
The publication of solid research findings (3,12) that 
characterize the pathogenesis and histology of GIST have 
created a discontinuity in the terminology used to describe 
this entity. Due to the unclear terminology of scientific 
literature published before 2000, it is very difficult to analyse 
and interpret the previous reports, but the researches 
published since then has significantly increased (4).
Herein, we aimed to perform a state-of-the-art review of 
available English literature to improve the understanding of 
dGIST and to outline the best options for surgical treatment.
Methods
Search strategy
Comprehensive research has been conducted to identify 
all clinical studies that report the occurrence of dGIST. 
The search was carried out on the electronic databases 
MEDLINE, Scopus, EMBASE and Cochrane Libraries. 
The research strategy included all studies published after 
2000 and focused on relevant articles using the following 
keywords: “gist”, “duodenal”, “stromal gastrointestinal 
cancer”, “surgery” and associated free terms. No language 
restrictions have been imposed to limit results.
Inclusion criteria
Studies were selected for consideration in this analysis 
provided they reported cases with dGIST. In order to select 
only those studies that certainly dealt with dGIST, only 
those studies in which the immunohistochemical analysis of 
the cKIT was reported and were positive were included.
Study selection
The inclusion criteria were used to examine the title, 
abstracts and full texts of the studies obtained from the 
research results. Two reviewers independently examined 
all citations on titles and abstracts produced by the search 
strategy and retrieved all potentially relevant reports. Two 
other independent readers then screened the full text of the 
studies to identify the entries that met the inclusion criteria. 
Any disagreements have been resolved by consensus. 
Differences in data extraction have been resolved by 
consensus, with references to the original article.
Results
The initial search produced 185 potentially relevant articles 
(Figure 1, Tables 1,2,3,4,5) that were suitable for subsequent 
screening. The titles and abstracts of these articles were 
screened to determine the relevance and eligibility for 
inclusion—53 papers were excluded for different reasons: 
Abstracts reviewed: 185
Articles excluded: 99
1. Non-duodenal GISTs
2. No surgery type reported
3. No patient data reported
4. No KIT reported
Articles reviewed: 86
Articles included in the systematic review: 86
Figure 1 Study selection process. 
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Table 1 Characteristics of included studies: pancreaticoduodenectomy
Study (year of 
publication)
Nation
Number of 
patients with 
duodenal GIST
Patient  
(age/gender)
Duodenal portion 
location
Symptoms and signs at admission
Takahashi 2001 (13) Japan 1 77; F Second Mild anemia
Uchida 2004 (14) Japan 1 53; F Extramural Asymptomatic
Hompes 2004 (15) Belgium 2 32; F Second Right superior abdominal discomfort
72; F Second Hypovolemic shock, melena, pallor, 
weakness, fatigue, anemia
Kim 2004 (16) Korea 1 37; F Second Weakness, nausea, melena, anemia
Sakakima 2004 (17) Japan 1 46; F Second Epigastralgia, melena, anemia
Sakakura 2006 (18) Japan 1 37; M Second Abdominal discomfort
Ludvigsen 2007 (19) Denmark 1 41; M Second Anemia
Fiore 2009 (20) Italy 3 49; F NR NR
66; M NR NR
71; M NR NR
Hecker 2010 (21) Germany 1 58 Second Recurrent episodes of upper abdominal 
pain, anemia, weight loss, fatigue and 
fever attacks, upper gastrointestinal 
bleeding after neoadjuvant imatinib 
Frampton 2010 (22) UK 1 37; F Second Right upper quadrant pain, sweating, 
nausea, hot flushes, palpitations
Wall 2010 (23) – 1 36; F – Diarrhea, bloating, weight loss, lethargy, 
collapse, melena, hypotension, 
tachycardia
Machado 2011 (24) Oman 1 58; M Second Melena, weight loss
Morcos 2011 (25) Jordan 1 38; F Second Epigastric discomfort, abdominal pain, 
anemia
Singh 2012 (26) India 1 30; M Second Mass in the right upper abdomen, 
abdominal pain 
Koontz 2012 (27) USA 1 36; F Third Upper gastrointestinal bleeding, 
abdominal fullness, early satiety, fatigue, 
anemia, syncope
Blandamura 2014 (28) Italy 1 72; M Third Increasing vomiting, weight loss
Bormann 2014 (29) Germany 1 64; F Second Slowly increasing pain in right upper 
abdomen
Kobayashi 2014 (30) Japan 1 36; M Second Loss of consciousness
Parisi 2014 (31) Italy 1 68 Second Fatigue, anemia, positive fecal occult 
blood
Bhambare 2015 (32) India 1 38; M Second Large abdominal lump, abdominal pain 
Okasha 2015 (33) Egypt 1 42; F Second Abdominal discomfort, melena, 
hematemesis
Niikura 2016 (34) Japan 1 75; M First Anemia, melena, hemorrhagic shock
Yamamoto 2016 (35) Japan 1 81; F Second Diarrhea
Tornambe 2017 (36) Italy 1 69; M Second Melena, asthenia, dizziness, severe 
anemia
NR, information not reported
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Table 2 Characteristics of included studies: local resection
Study  
(year of publication)
Nation
Number of 
patients with 
duodenal GIST
Patient  
(age; gender)
Duodenal portion 
location
Symptoms and signs at admission
Sawaki 2003 (37) Japan 1 54; F First Asymptomatic
Sakamoto 2003 (38) Japan 1 31; F Third NR
Kurihara 2005 (39) Japan 1 64; M Second Tarry stools, dizziness, and severe 
anemia
Goh 2005 (40) Singapore 2 72; F Second Epigastralgia, melena, anemia
69; M Second and third Abdominal discomfort
Cavallini 2005 (41) Italy 1 66; F Second Anemia, melena
Vu 2005 (42) Japan 1 43; M Third NR
Towu 2006 (43) UK 1 7; M Second and third Severe upper gastrointestinal bleeding
Kwon 2007 (44) Korea 1 49; M Second and third Asymptomatic
Graham 2007 (45) UK 1 57; M Fourth Melena, anemia
Gupta 2007 (46) USA 1 63; M Second and third Gastrointestinal bleeding
Mohiuddin 2007 (47) UK 1 56; M Second Melena, anemia
Fernández Salazar 
2007 (48)
Spain 1 44; M NR GI bleeding
Mennigen 2008 (49) Germany 1 29; M Third Acute upper gastrointestinal bleeding
Takahashi 2009 (50) Japan 1 57; F First Bloody stools
Takeuchi 2009 (51) Japan 1 55; M Third Asymptomatic
Seçkin 2009 (52)  Turkey 1 56; M Third Melena, anemia
Hirashima 2009 (53) Japan 1 68; F NR Asymptomatic
Mehta 2011 (54) USA 1 33; F Third Melena, dizziness, anemia, 
hypotension, tachycardia
Chung 2011 (55) Korea 2 65; M Third Abdominal pain 
49; F Fourth Upper gastrointestinal bleeding, 
melena
Cameron 2011 (56) Germany 1 62; M Second NR
Kato 2011 (57) Japan 1 60; M Third NR
Chen 2012 (58) Australia 1 52; M NR Anemia
El-Gendi 2012 (59) Egypt 12 60; F,  
n=5, M, n=7
First, n=3 Melena, anemia
Second n=1
Third, n=3
Fourth, n=1
Acar 2013 (60) Turkey 1 65; F Third Abdominal pain
Mouaqit 2013 (61) Morocco 1 65; F Second and third Abdominal pain, anemia
Mokhtare 2013 (62) Iran 1 2; M Third Acute upper gastrointestinal bleeding
Table 2 (continued)
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Table 2 (continued)
Study  
(year of publication)
Nation
Number of 
patients with 
duodenal GIST
Patient  
(age; gender)
Duodenal portion 
location
Symptoms and signs at admission
Shaw 2013 (63) UK 1 61; M Third and fourth Hypovolemic shock, upper 
gastrointestinal bleeding, melaena, 
hematemesis, temporary loss of 
consciousness
Ueda 2014 (64) Japan 1 72; F Third Asymptomatic
Hankiewicz-
Ziołkowska 2014 (65)
Poland 1 65; F First Asymptomatic
Manxhuka-Kerliu  
2014 (66)
Kosovo 1 30 Fourth-jejunum Abdominal pain, nausea, vomiting
Fukuyama 2014 (67) Japan 1 69; M Second Anemia, melena
Borgaonkar 2015 (68) India 2 52; F NR NR
23; M NR NR
Jones 2015 (69) USA 2 40; F NR Epigastric pain, recurrent 
gastrointestinal bleeding
29; F Second Asymptomatic
Mrak 2015 (70) Austria 1 68; F Upper portions Abdominal pain, melena, hemodynamic 
instability
Kumar 2015 (71) India 1 55; F Second and Third Epigastric pain
Chung 2015 (72) Korea 21 59; F,  
n=9, M, n=12
First, n=7 Incidental finding, abdominal pain, 
bleeding
Second, n=5
Third, n=5
Fourth, n=4
Graziosi 2015 (73) Italy 1 51; F Second Anemia, melena
Boselli 2016 (74) Italy 3 75; F Fourth Melena, anemia
82; F Passage between 
second and third
Melena, syncope, anemia, 
hemodynamic instability
76; M Passage between 
second and third
Melena, syncope, anemia, 
hemodynamic instability
Caruso 2016 (75) Italy 1 73 Fourth, duodenojejunal 
junction
Anemia, melena
Jones 2016 (76) USA 1 71; F Second Recurrent GI bleeding
Turculeţ 2016 (77) Romania 1 48; M Third and Fourth Melena, asthenia, dizziness, severe 
anemia 
Huo 2016 (78) China 1 58; F First Epigastric abdominal discomfort, 
diarrhea, recurrent vomiting
Mori 2016 (79) Japan 1 74; M Third NR
Valli 2016 (80) Switzerland 1 19; F Second Fainting, anemia, melena
Table 2 (continued)
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Table 2 (continued)
Study  
(year of publication)
Nation
Number of 
patients with 
duodenal GIST
Patient  
(age; gender)
Duodenal portion 
location
Symptoms and signs at admission
Crocetti 2016 (81) Italy 9 70; F,  
n=9, M, n=12
NR Pain, bleeding, dyspepsia
Thillai 2017 (82) India 1 50; F Second and third Abdominal pain
Elston 2017 (83) Australia 1 29; M Second Acute upper gastrointestinal 
hemorrhage, melena
Vasile2017 (84) Romania 1 59; F First and second Abdominal pain, upper gastrointestinal 
bleeding (melena), faintness, anemia
Zioni2017 (85) Israel 1 68; M Second and third Upper gastrointestinal bleeding, 
general weakness, melena, anemia
Perfetti2017 (86) Italy 1 33; M Second Gastrointestinal bleeding, anemia
Hakozaki 2017 (87) Japan 1 70; F First Positive fecal occult blood test
NR, information not reported.
Table 3 Characteristics of included studies: PD and local resections
Study  
(year of publication)
Nation
Number of patients 
with duodenal GIST
Patients  
(age; gender)
Duodenal portion 
location
Symptoms and sign at admission
Miettinen 2003 (9) USA 156 56; F, n=71,  
M, n=85
First, n=10 Anemia, melena, obstruction, acute 
abdomenSecond, n=42
Third, n=17
Second-third, n=7
Fourth, n=11
Relles 2009 (88) USA 2 43; M Second Melena, fatigue, shortness of breath
31; M Ligament of Treitz Solid food dysphagia, abdominal 
discomfort
Tien 2010 (89) Taiwan 25 62; F, n=9,  
M, n=16
3 first Bleeding, pain, mass
13 second
5 third
4 fourth
Miki 2010 (90) Japan 6 64; F Second Melena
70; F Fourth Abdominal mass
67; F First Asymptomatic
39; F First Melena
65; M Second Anemia
75; F Second Anemia
Yagishita 2011 (91) Japan 4 62; F Second NR
69; M First NR
76; M Second Anemia
72; M First NR
Table 3 (continued)
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Table 3 (continued)
Study  
(year of publication)
Nation
Number of patients 
with duodenal GIST
Patients  
(age; gender)
Duodenal portion 
location
Symptoms and sign at admission
Liang 2013 (92) Japan 28 28; F Second Melena
48; F Second Asymptomatic
60; M Second Melena
70; M Second Abdominal pain
71; M Third Asymptomatic
76; F Second Melena
42; F Second Melena
74; M First Melena
53; F First Melena
47; F Second Melena
55; F Fourth Melena
51; M Second Melena
50; M Second Hematemesis
69; F Third Abdominal pain
65; M Third Melena
63; M Second Acute abdomen
44; F Second Hematemesis
57; F Third Discomfort
20; F Second Melena
52; M Fourth Abdominal pain
53; F Second Abdominal pain
71; F Second Early satiety
53; M First Early satiety
50; F First Melena
46; F Second Abdominal pain
55; M Second Melena
51; M Third Asymptomatic
46; F Second Melena
Hoeppner 2013 
(93)
Germany 9 51; M Second Bleeding
63; M Third Bleeding
52; M First Bleeding
62; F First Jaundice
58; M First Abdominal pain
69; F Second Incidental finding
43; F Fourth Bleeding
75; M Third Bleeding
49; F Second Bleeding
Table 3 (continued)
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Table 3 (continued)
Study  
(year of publication)
Nation
Number of patients 
with duodenal GIST
Patients  
(age; gender)
Duodenal portion 
location
Symptoms and sign at admission
Yang 2013 (94) China 22 58; F, n=7,  
M, n=15
First, n=3 Asymptomatic, abdominal discomfort/
pain, melena, weight loss, fatigue, 
abdominal distension, anorexia, back 
pain, hematemesis, jaundice, anemia, 
palpable abdominal mass
Second, n=14
Third-fourth, n=5
Zhou 2013 (95) China 48 53; F, n=20,  
M, n=28
First, n=11 Bleeding, abdominal pain, abdominal 
discomfort, jaundice
Second, n=17
Third, n=6
Fourth, n=2
First-second, n=2
Second-third, n=4
Duffaud 2014 (96) France 114 57; F, n=55,  
M, n=59
First, n=8 Pain, GI bleeding, anemia, 
asymptomatic
Second, n=38
Third, n=27
Fourth, n=15
Ucar 2015 (97) Turkey 2 65; M First Upper gastrointestinal bleeding
60; M Second Ileus, acute abdomen, hemorrhagic 
pancreatitis
Lv 2017 (98) China 10 44; F Third Abdominal pain
50; M Second Asymptomatic
43; M Second Melena
50; F Second and third Abdominal pain
60; M Second Abdominal discomfort
44; M Second Abdominal discomfort
50; F Third Melena
44; M Second and third Melena
65; M Second Melena
64; F Third Abdominal pain
NR, information not reported.
Table 4 Characteristics of included studies: PD and local resections
Study (year of publication)
Histologic characteristics
c-kit DOG1 CD34 Smooth muscle actin S100 Desmin
Miettinen 2003 (9) 109 NR 49 38 19 No
Relles 2009(88)
Yes NR Yes NR No NR
Yes No Yes No No No
Tien 2010 (89) 25 NR 5 5 4 No
Table 4 (continued)
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Table 4 (continued)
Study (year of publication)
Histologic characteristics
c-kit DOG1 CD34 Smooth muscle actin S100 Desmin
Miki 2010 (90) Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yagishita 2011 (91) Yes No Yes No No NR
Yes No Yes No No NR
Yes No Yes No No NR
Yes No No No No NR
Liang 2013 (92) Yes NR No Yes No No
Yes NR Yes Yes No NR
Yes NR No Yes No NR
Yes NR Yes Yes Yes NR
Yes NR Yes Yes No NR
Yes NR Yes No Yes No
Yes NR No Yes Yes No
No NR Yes No No NR
Yes NR Yes Yes Yes NR
Yes NR No Yes Yes NR
Yes NR Yes No Yes NR
Yes NR Yes No Yes NR
Yes NR Yes Yes No NR
Yes NR Yes Yes No NR
Yes NR Yes Yes No NR
Yes NR Yes No Yes NR
Yes NR Yes No Yes NR
Yes NR Yes No No NR
Yes NR No Yes No No
Yes NR Yes No No No
Yes NR No Yes No NR
Yes NR Yes No No No
Yes NR No Yes Yes No
Yes NR No Yes No No
Yes NR No Yes No NR
Yes NR No No Yes NR
Yes NR Yes No No No
Yes NR Yes Yes Yes NR
Table 4 (continued)
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Table 4 (continued)
Study (year of publication)
Histologic characteristics
c-kit DOG1 CD34 Smooth muscle actin S100 Desmin
Hoeppner 2013 (93) Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yang 2013 (94) 18 NR 17 10 8 No
Zhou 2013 (95) 47 NR 32 NR 5 6
Duffaud 2014 (96) 105 NR 58 NR NR NR
Ucar 2015 (97) Yes Yes Yes NR NR NR
Yes Yes Yes NR NR NR
Lv 2017 (98) Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
Yes NR NR NR NR NR
NR, information not reported.
Table 5 Characteristics of included studies: PD and local resections
Study  
(year of publication)
Tumor extension 
out duodenum
Type of treatment
Neoadjuvant 
treatment with 
Imatinib
Postoperative 
treatment with 
Imatinib
Survival (years; 
months)
Miettinen 2003 (9) Duodenum 15 enucleation; 48 segmental 
resection; 21 wedge resection; 21 
pancreaticoduodenectomy; 51 NR
NR NR NR
Relles 2009 (88) Duodenum Pancreaticoduodenectomy NR NR NR
Duodenum Local resection NR NR NR
Tien 2010 (89) Duodenum 9 pancreaticoduodenectomy;  
16 local resection
NR NR NR
Table 5 (continued)
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Table 5 (continued)
Study  
(year of publication)
Tumor extension 
out duodenum
Type of treatment
Neoadjuvant 
treatment with 
Imatinib
Postoperative 
treatment with 
Imatinib
Survival (years; 
months)
Miki 2010 (90) Duodenum Duodenectomy NR No NR
Local resection NR Yes NR
Local resection NR No NR
Local resection NR No NR
Local resection NR No NR
Pancreaticoduodenectomy NR No NR
Yagishita 2011 (91) Duodenum Partial duodenectomy NR NR NR
Duodenum No treatment NR NR NR
Duodenum No treatment NR NR NR
Duodenum, 
pancreas
Pancreaticoduodenectomy NR NR NR
Liang 2013 (92) Duodenum Segmental resection No No 164 m
Wedge resection No 146 m
Pancreaticoduodenectomy No 61 m
Pancreaticoduodenectomy No 35 m
Segmental resection No 23 m
Segmental resection No 25 m
Pancreaticoduodenectomy No 73 m
Wedge resection No 61 m
Segmental resection No 116 m
Pancreaticoduodenectomy No 111 m
Segmental resection No 55 m
Pancreaticoduodenectomy No 23 m
Wedge resection No 102 m
Pancreaticoduodenectomy No NR
Segmental resection No 68 m
Pancreaticoduodenectomy No 49 m
Pancreaticoduodenectomy No 33 m
Segmental resection No 57 m
Segmental resection No 86 m
Segmental resection No 33 m
Wedge resection No 40 m
Segmental resection No 59 m
Wedge resection No 75 m
Segmental resection No 73 m
Segmental resection Yes 71 m
Pancreaticoduodenectomy No 70 m
Segmental resection Yes 63 m
Pancreaticoduodenectomy No 61 m
Table 5 (continued)
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Table 5 (continued)
Study  
(year of publication)
Tumor extension 
out duodenum
Type of treatment
Neoadjuvant 
treatment with 
Imatinib
Postoperative 
treatment with 
Imatinib
Survival (years; 
months)
Hoeppner 2013 (93) Duodenum Open wedge resection No No 6 m
Open wedge resection No Yes 7 m
Laparoscopic wedge resection No No 13 m
Pancreaticoduodenectomy No No Died at 3 m
Open wedge resection No No 90 m
Open wedge resection No No 111 m
Segmental resection No No 92 m
Open wedge resection Yes No Died at 37 m
Tumor resection Yes Yes 39 m
Yang 2013 (94) Duodenum 9 pancreaticoduodenectomy; 13 
local resection
No 5 NR
Zhou 2013 (95) Duodenum 34 local resection; 14 
pancreaticoduodenectomy
NR NR NR
Duffaud 2014 (96) Duodenum 82 local resection; 23 
pancreaticoduodenectomy
11 20 NR
Ucar 2015 (97) Duodenum Local resection NR NR NR
Pancreaticoduodenectomy NR NR NR
Lv 2017 (98) Duodenum Segmental resection Yes NR 36 m
Tumor resection Yes NR 50 m
Radical resection Yes NR 44 m
Segmental resection Yes NR 47 m
Tumor resection Yes NR 17 m
Tumor resection Yes NR 36 m
Segmental resection Yes NR 17 m
Radical resection Yes NR 16 m
Segmental resection Yes NR 16 m
Pancreaticoduodenectomy Yes NR 41 m
NR, information not reported.
non-duodenal GISTs, no surgery type reported, and no 
patient data reported leaving 132 studies for inclusion in 
the present review. Of them, 46 studies did not report the 
data about cKIT and were excluded thus leaving 86 studies 
included in the analysis. The patients excluded for non-
duodenal GIST were 7,142, those excluded for no surgery 
type reported were 1,039 and 1,002 patients were excluded 
because of no cKIT reported. The characteristics of the 
included studies have been summarized in Tables 1,2,3,4,5. 
All studies were published between 2001 and 2017. Eighty-
two papers with 539 cases reported data on the signs and 
symptoms at the time of hospital admission, whereas in 
four studies there were no data. Upon admission, the most 
common symptoms were GI bleeding and melena, followed 
by abdominal pain and discomfort. Symptoms of fatigue, 
fainting, vomiting, and ankle edema were also reported but 
occurred far less frequently. In the majority of cases dGISTs 
were located in the second portion of the duodenum. 
Several cases reported dGIST localization in both the 
second and third portions of the duodenum.
The included studies summoned a total of 549 patients with 
dGIST—27 patients treated with pancreatoduodenectomy 
(PD) (Table 1), 96 patients treated with local resection (Table 2), 
and 426 patients treated with either PD or segmental/wedge 
resections (Tables 3,4,5).
Among patients treated with PD (Tables 1,6), the majority 
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Table 6 Characteristics of included studies: pancreaticoduodenectomy
Study  
(year of publication)
Local tumor extension 
Surgical 
access
Neoadjuvant 
treatment with 
imatinib
Postoperative 
treatment with 
imatinib
Multivisceral 
resection
Survival (years, 
months)
Takahashi 2001 (13) Duodenum, pancreatic head, 
gall bladder, gastric antrum, 
regional lymph nodes
Open NR NR Gastric antrum NR
Uchida 2004 (14) Duodenum Open No No No NR
Hompes 2004 (15) Duodenum, pancreas, 
mesocolon
Open No No Ascending colon NR
Kim 2004 (16) Duodenum Open No No No 5 m
Sakakima 2004 (17) Duodenum Open NR NR No NR
Sakakura 2006 (18) Duodenum Open No Yes No 24 m
Ludvigsen 2007 (19) Duodenum, hilum, liver, right 
kidney, right hemicolon, right 
hemipancreas, celiac trunk, 
inferior vena cava, right renal 
vein, right renal pelvis
Open Yes Yes Right kidney, 
adrenal gland
NR
Fiore 2009 (20) Duodenum Open Yes NR No NR
Yes NR No NR
Yes NR No NR
Hecker 2010 (21) Duodenum, pancreas, right 
flexure of the colon
Open Yes Yes Right hemicolon NR
Frampton 2010 (22) Duodenum Open NR NR No NR
Wall 2010 (23) Duodenum Open No No No NR
Machado 2011 (24) Duodenum, right hemicolon Open No Yes Right hemicolon 2 m
Morcos 2011 (25) Duodenum Open No No No 34 m
Singh 2012 (26) Duodenum Open No Yes No NR
Koontz 2012 (27) Duodenum Open Yes Yes No NR
Blandamura 2014 (28) Duodenum Open No No No NR
Bormann 2014 (29) Duodenum, pancreas Open No No No NR
Kobayashi 2014 (30) Duodenum Open No No No 18 m
Bhambare 2015 (32) Duodenum Open No Yes No NR
Okasha 2015 (33) Duodenum Open No No No NR
Niikura 2016 (34) Duodenum Open No Yes No 6 y
Yamamoto 2016 (35) Duodenum Open No No No NR
Tornambe 2017 (36) Duodenum Open No No No 12 m
NR, information not reported.
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were females (n=14, 52%; males: n=11, 41%; not reported: 
n=2, 7%), with a median age of 50 years (Table 1). Most 
patients presented with symptoms of anemia (n=11, 40%), 
melena (n=8, 27%), fatigue (n=4, 15%), and weight loss 
(n=4, 15%). However, in 3 patients the information was not 
reported. For most patients, the dGIST were located in the 
second portion of the duodenum (first: n=1, 4%; second: 
n=19, 70%; third: n=1, 4%; not reported: n=5, 18%) (Table 1). 
Four studies (13,19,21,25) reported dGIST tumors that 
extended beyond the duodenum. All PDs were performed 
by open procedure. While some patients received imatinib 
as a neoadjuvant treatment (n=7, 26%), a greater proportion 
received the treatment post-operatively (n=9, 33%) (Table 6). 
For most patients, no long term survival data were reported 
(n=21, 75%). Notably, the PD studies reported histological 
information on KIT, DOG1, or CD34. 
Among patients treated with local resection (Tables 2,7) 
there was a slight preponderance of males (n=51, 53%; 
females: n=45, 47%) with a median age of 57.3 years (Table 2). 
Upon admission, patients most commonly presented with 
nausea (n=1, 1%), abdominal pain (n=8, 8%), undetermined 
pain (n=18, 19%), melena (n=20, 21%), dizziness (n=3, 3%), 
and/or GI bleeding (n=14, 16%). No data on presenting 
signs and symptoms was available for 7 patients (Table 2). 
Within this group, most dGIST were located in the 
second and third portions of the duodenum (first: n=16, 
17%; second: n=29, 30%, third: n=32, 33%; fourth: n=12, 
12%; not reported: n=7, 7%), with tumors extending beyond 
the duodenum in four cases. For all local resections reported, 
surgical access was predominantly achieved by either 
open (n=89, 92%) or laparoscopic procedure (n=5, 5%). 
Patients treated with a local resection received less 
neoadjuvant (n=13, 13%) and post-operative (n=22, 23%) 
treatment with imatinib (Table 8), as compared to patients 
treated with a pancreaticoduodenectomy (Table 6), and four 
patients underwent multiple visceral resections.
Of the patients whose histological or molecular data 
were provided (Table 7), most tested positive for cKIT (n=85, 
46%), CD34 (n=48, 26%) and DOG1 (n=20, 11%). A 
minority of patients tested positive for either smooth muscle 
actin (n=5, 3%), S100 (n=7, 4%) or desmin (n=1, 1%). 
Four hundred twenty-six patients were treated with 
either PD or segmental/wedge resections. Within this 
group, there was preponderance of males (n=218, 51%) vs. 
females (n=183, 43%), not reported (n=25, 6%). At the time 
of admission, patients frequently presented with symptoms 
of bleeding (n=137, 32%), abdominal pain or discomfort 
(n=258, 60%) and melena (n=235, 55%). Five patients were 
asymptomatic (Tables 3,4,5). dGISTs were predominantly 
located in the second and third portions of the duodenum 
in this group (first: n=47, 11%; second: n=164, 38%; 
third: n=83, 19%; fourth: n=41, 9%). In many cases the 
tumors extended into multiple portions of the duodenum 
simultaneously. All of these studies reported data on cKIT 
and several studies reported data on CD34 and DOG1.
Within this cohort the most common type of surgical 
treatment was local resection (n=151, 35%), followed by 
PD (n=92, 21%) and segmental (n=97, 15%) or wedge 
resections (n=32, 7%). No data on the type of surgical 
treatment were available for 51 patients. Within this group 
of patients, both neoadjuvant and post-operative treatment 
with imatinib were rarely applied (neoadjuvant treatment: 
n=23, 5%; adjuvant treatment: n=30, 7%). Most patients 
received no imatinib treatment prior to surgery (n=160, 
38%) or post-operatively (n=149, 35%).
Surgical treatment
There are three main surgical options: pancreatoduodenectomy 
(PD) (10,24), wedge resection (40,60,63,97) and segmental 
resection. PD is indicated in the cases with involvement of 
major duodenal papilla, pancreas or pancreatic duodenal 
wall and is required in 20–40%. Based on the literature, the 
following options for surgical reconstruction according to the 
localization and extent of duodenal resection are available:
First and second duodenal portions:
 wedge resection with primary transverse closure 
of duodenum (39) or retrocolic Roux-en-Y loop to 
cover a large defect (97);
 segmental resection, closure of distal stump and 
duodenojejunostomy by retrocolic Roux-en-Y loop (99);
 segmental resection with antrectomy with side-to-side 
posterior or Roux-en-Y gastrojejunostomy (55,59);
 s u b t o t a l  r e s e c t i o n  w i t h  s i d e - t o - s i d e 
duodenojejunostomy (100);
 sleeve resection with gastroduodenostomy (the case 
with situs inversus totalis) (82);
 ampullectomy with sphincteroplasty (55).
Third and fourth duodenal portions:
 segmental resection with closure of distal stump 
and side-to-side (93) or end-to-side/end-to-end 
duodenojejunostomy (62,92);
 segmental resection, end-to-end anastomosis, 
pylorus closure and gastroenterostomy with/without 
feeding jejunostomy (77);
 segmental resection, closure of distal stump near leg. 
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Table 7 Characteristics of included studies: local resection
Study (year of publication)
Histologic characteristics
C-kit/CD117 DOG1 CD34/PDGFR-alfa Smooth muscle actin S100 Desmin
Sawaki 2003 (37) Yes NR Yes No No No
Sakamoto 2003 (38)  Yes NR NR NR NR NR
Kurihara 2005 (39) Yes NR Yes Yes No No
Goh 2005 (40) Yes NR NR NR NR NR
Yes NR NR NR NR NR
Cavallini 2005 (41) Yes NR NR No Yes No
Vu 2005 (42) Yes NR No Yes No No
Towu 2006 (43) Yes NR No No NR NR
Kwon 2007 (44) Yes NR Yes No NR NR
Graham 2007 (45) Yes NR Yes NR NR NR
Gupta 2007 (46) Yes NR NR No No NR
Mohiuddin 2007 (47) Yes NR NR NR NR NR
Fernández Salazar 2007 (48) Yes NR NR NR Yes NR
Menningen 2008 (49) Yes NR Yes No No NR
Takahashi 2009 (50) Yes No Yes No Yes No
Takeuchi 2009 (51) Yes NR Yes No No NR
Seçkin 2009 (52) Yes NR Yes NR Yes NR
Hirashima 2009 (53) Yes NR Yes NR No No
Mehta 2011 (54) Yes No Yes Yes No No
Chung 2011 (55) Yes NR NR NR NR NR
Yes NR NR NR NR NR
Cameron 2011 (56) Yes NR NR NR NR NR
Kato 2011 (57) Yes NR NR NR NR NR
Chen 2012 (58) Yes NR NR NR NR NR
El-Gendi 2012 (59) 12 NR 8 NR 2 No
Acar 2013 (60) Yes NR NR NR Yes NR
Mouaqit 2013 (61) Yes NR Yes NR NR NR
Mokhtare 2013 (62) Yes Yes Yes NR NR NR
Shaw 2013 (63) Yes NR Yes NR NR NR
Ueda 2014 (64) Yes NR Yes NR NR NR
Hankiewics-Ziolkowska 2014 (65) Yes NR Yes NR NR NR
Manxhuka-Kerliu 2014 (66) Yes NR Yes Yes No No
Table 7 (continued)
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Table 7 (continued)
Study (year of publication)
Histologic characteristics
C-kit/CD117 DOG1 CD34/PDGFR-alfa Smooth muscle actin S100 Desmin
Fukuyama 2014 (67) Yes NR NR NR NR NR
Mrak 2015 (70) Yes No No No No No
Kumar 2015 (71) Yes NR Yes NR NR NR
Chung 2015 (72) 21 NR 14 NR 10 No
Graziosi 2015 (73) Yes Yes NR NR NR NR
Boselli 2016 (74) Yes Yes Yes No No No
Yes Yes No No No No
No No No No No Yes
Caruso 2016 (75) Yes No Yes No No No
Jones 2016 (76) Yes NR Yes No No No
Turculeţ 2016 (77) Yes Yes No Yes No NR
Huo 2016 (78) Yes No Yes No No No
Mori 2016 (79) Yes Yes No No No No
Valli 2016 (80) Yes Yes Yes No No No
Crocetti 2016 (81) Yes Yes NR NR NR NR
Thillai 2017 (82) Yes No Yes No No No
Elston 2017 (83) Yes Yes No No No No
Vasile 2017 (84) Yes NR Yes No No NR
Zioni 2017 (85) Yes NR NR NR NR NR
Perfetti 2017 (86) Yes Yes Yes No No No
Hakozaki 2017 (87) Yes NR Yes NR No NR
Table 8 Characteristics of included studies: local resection
Study  
(year of publication)
Tumor extension out 
duodenum
Type of surgical 
access
Neoadjuvant 
treatment with 
Imatinib
Postoperative 
treatment with 
Imatinib
Multiple visceral 
resection
Survival  
(years; months)
Sawaki 2003 (37) Duodenum Open No Yes No NR
Sakamoto 2003 (38) Duodenum Open No No No NR
Kurihara 2005 (39) Duodenum Open No No No NR
Goh 2005 (40) Duodenum Open No No No NR
Duodenum, transverse 
mesocolon, small 
bowel mesentery
Open No No Small bowel 
resection and 
transverse 
colectomy
NR
Cavallini 2005 (41) Duodenum Open No No No 4 y
Table 8 (continued)
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2018;3:71tgh.amegroups.com
Page 17 of 27Translational Gastroenterology and Hepatology, 2018
Table 8 (continued)
Study  
(year of publication)
Tumor extension out 
duodenum
Type of surgical 
access
Neoadjuvant 
treatment with 
Imatinib
Postoperative 
treatment with 
Imatinib
Multiple visceral 
resection
Survival  
(years; months)
Vu 2005 (42) Duodenum Open NR NR NR NR
Towu 2006 (43) Duodenum Open No No No NR
Kwon 2007 (44) Duodenum Open No No No NR
Graham 2007 (45) Duodenum NR No Yes No NR
Gupta 2007 (46) Duodenum Open No No No NR
Mohiuddin 2007 (47) Duodenum Open No Yes No 42 m
Fernández Salazar  
2007 (48)
Duodenum Open NR NR No NR
Mennigen 2008 (49) Duodenum Open No No No NR
Takahashi 2009 (50) Duodenum NR No No No NR
Takeuchi 2009 (51) Duodenum Open No No No 24 m
Seçkin 2009 (52) Duodenum Open NR NR No NR
Hirashima 2009 (53) Duodenum Open No No No NR
Mehta2011 (54) Duodenum NR No No No NR
Chung 2011 (55) Duodenum Open No No No 42 m
Open No No No 13 m
Cameron 2011 (56) Duodenum Open No Yes No 10 y
Kato 2011 (57) Duodenum Laparoscopic-
endoscopic
NR NR No NR
Chen 2012 (58) Duodenum Open NR NR No NR
El-Gendi 2012 (59) Duodenum Open No 10 No 45 m
Acar 2013 (60) Duodenum Open No No No NR
Mouaqit 2013 (61) Duodenum Open No Yes No 24 m
Mokhtare 2013 (62) Duodenum Open No No No NR
Shaw 2013 (63) Duodenum Open NR NR No NR
Ueda 2014 (64) Duodenum Laparoscopic No No No NR
Hankiewics-Ziolkowska 
2014 (65)
Duodenum Open No No No NR
Manxhuka-Kerliu  
2014 (66)
Duodenum, jejunum Open No No No NR
Fukuyama 2014 (67) Duodenum Open Yes Yes No 12 m
Borgaonkar 2015 (68) Duodenum Open NR 2 No NR
Jones 2015 (69) Duodenum Open Yes Yes No NR
Mrak 2015 (70) Duodenum Open No Yes No NR
Kumar 2015 (71) Duodenum Open No No No 6 m
Table 8 (continued)
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Treitz and end-to-side duodenojejunostomy with 
first jejunal loop (99);
 segmental resection with end-to-side or end-
to-end duodenojejunostomy to the left of the 
superior mesenteric vessels (66,72,75) segmental 
resection, closure of distal stump on the right of 
superior mesenteric vessels, papilloplasty, end-
to-side duodenojejunostomy, transcystic tube and 
transjejunal tubes draining the main pancreatic duct 
and decompressing duodenum (38);
 segmental resection of third and fourth part of 
duodenum, closure of second portion stump and 
side-to-end duodenojejunostomy (49);
Discussion
Duodenal GIST is typically seen in individuals between the 
ages of 60–70 years old. There were few papers reporting 
an occurrence of dGIST in children and teenagers, all of 
which manifested with severe bleeding (80,97,101). The 
median age of the patients with dGIST is 56 years with a 
slight preponderance of males (54% vs. 46%) (1,5).
Risk factors
Most cases are sporadic, whereas familial clustering is 
reported in only 1.5–4% of the cases (69,102). Familial 
Table 8 (continued)
Study  
(year of publication)
Tumor extension out 
duodenum
Type of surgical 
access
Neoadjuvant 
treatment with 
Imatinib
Postoperative 
treatment with 
Imatinib
Multiple visceral 
resection
Survival  
(years; months)
Chung 2015 (72) Duodenum 19 open, 2 
laparoscopic
No No No NR
Graziosi 2015 (73) Duodenum Open No Yes No NR
Boselli 2016 (74) Duodenum Open No No No NR
Duodenum Open No No No NR
Duodenum Open No No No NR
Caruso2016 (75) Duodenum, jejunum Open No No No NR
Jones 2016 (76) Duodenum Open No No No NR
Turculeţ 2016 (77) Duodenum Open No No No NR
Huo 2016 (78) Duodenum Open No No No 12 m
Mori 2016 (79) Duodenum Open No No No NR
Valli 2016 (80) Duodenum Open Yes No No NR
Crocetti 2016 (81) NR Open Yes No No NR
Thillai 2017 (82) Duodenum, adherent 
to ascending colon 
and Gerota’s fascia
Open No Yes No NR
Elston 2017 (83) Duodenum Open No No No NR
Vasile 2017 (84) Duodenum Open No Yes Gastric antrum, 
distal common bile 
duct, pancreatic 
head
24 m
Zioni 2017 (85) Duodenum Laparoscopic No No No 1,5 y
Perfetti 2017 (86) Duodenum Open Yes Yes No 1,5 y
Hakozaki 2017 (87) Duodenum Open No No No NR
NR, information not reported.
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GIST is an autosomal dominant condition caused by 
germline mutations of cKIT or PDGFRA and manifests 
at earlier age. GIST may be part of Carney’s triad (gastric 
GIST, paraganglioma, and pulmonary chondroma) or 
Carney-Stathakis syndrome, which are caused by germline 
mutations in SDH (89). It is a well-known fact that 
von Recklinghausen neurofibromatosis type 1 (NF 1) is 
associated with an increased risk for GIST. GISTs in NF 
1 occur in 6–7%, affect duodenum in 22–31%, and tend 
to be smaller, multiple and with lower mitotic count and 
occur at younger age (89,103,104). Hakozaki et al. described 
a case of dGIST and rectal cancer in a patient with 
NF 1 (87). Malignant carcinoid of ampulla Vateri and 
bilateral feochromocitoma have been also described with 
low responses to imatinib (105). Few papers reported 
extremely rare combination with pancreatic neuroendocrine 
neoplasia (64) and somatostatinoma in NF 1 (35) and 
Brunner’s gland cysts (78).
Localization
Most dGISTs develop in the second (59–63%) and 
third portion (22%) of duodenum (55,106), whereas the first 
and forth are less frequently affected. GIST of ampulla Vateri 
is extremely rare and according to the review of Kobayashi 
et al. only 12 cases have been described till 2014 (30). In all 
cases pain, jaundice and melena were the most frequent 
symptoms. Despite its rarity, this localization requires 
meticulous differential diagnosis (neuroendocrine tumors, 
carcinoma, paraganglioma) because usually the radical 
treatment requires PD (107).
Histopathology and molecular characteristics
Histologically, dGISTs do not differ from other GIST 
localizations. The most frequently reported pattern was 
spindle cell (67%), but epithelioid (11%), pleomorphic, 
mixed (22%), hemangioma-like or hemangiopericytoma-
like patterns can also be seen (9,13,55,93,99,101,108-114). 
Immunohistochemistry staining of the specimens 
revealed the following distribution of the markers: 
CD117 (c-kit) (92–100%), and less frequently CD34 
(54–70%), smooth muscle actin (20–30%), S-100 protein 
(10–20%), and neurofilament 68 (14%), DOG1 protein 
(6%) (9,12,65,94,115). Lack of DOG-1 expression was 
associated with poor prognosis in a recent study with 
332 patients (93). The differential diagnosis includes 
f ib romatos i s  (110 ) ,  s chwannomas ,  l e iomyomas , 
inflammatory fibroid tumors, solitary fibrous tumor, 
mesenteric  sc lerosing f ibrotic  les ions,  sarcomas, 
metastasis from malignant melanoma, glomus tumors, 
paragangliomas, ectopic pancreas (65,92,98).
At the molecular level, approximately 96% of GISTs 
have cKIT (CD117) mutation, typically in exon 11, but 
mutations in exons 9, 13, and 17 may also occur (101). Exon 
11 mutations carry a better prognosis and respond well 
to standard dose (400 mg/dayly) of imatinib (116). Some 
authors reported worse outcomes in exon 9 mutation (102). 
Approximately 8% of the cases have PDGRFA mutation, 
which is mutually exclusive with cKIT but is associated with 
longer relapse-free interval (43,59,116). Some PDGFRA 
are resistant to imatinib (65). The so-called wild type is 
observed in 10–15% of the cases and in 90% of children. 
It is caused by germline mutations in BRAF V600E, 
RAS family or succinate dehydrogenase subunits (SDH 
A-D). GISTs in NF1 are usually wild type with possible 
implication of RAS-MAPK pathway (104,117-119). This 
subset of GISTs is relatively resistant to the treatment with 
imatinib. Further large studies are needed to elucidate the 
individual prognosis according to the mutational status.
Clinical manifestation
Approximately 70% of the cases manifest with symptoms, 
while 21% are found incidentally and 10% on autopsy (120). 
Our analysis revealed that in contrast to the other 
localizations the most frequent manifestation of dGIST 
is the upper gastrointestinal bleeding, which is in 
accordance with the literature (21,74,121). Constant/
intermittent dull pain/discomfort or abdominal palpable 
mass are less frequent initial symptoms (10,32,71). 
Rarely, however, dGISTs may have various initial 
presentations leading to misdiagnosis. Millonig et al. 
reported extrahepat ic  cholestas is  and Takotsudo 
cardiomyopathy in a patient with undiagnosed NF1 (122). 
The extremely rare dGIST of ampulla Vateri can also 
manifest with jaundice (30). In certain cases, extramural 
growth may mimic pancreatic head tumor (26,44,84,97), 
large duodenal cyst (61), bleeding or uncomplicated 
duodenal diverticula (33, 46). Wall et al. reported a 
rare case with duodenal-jejunal intussusception (23). 
Lin et al. described two cases with bleeding small dGISTs 
(<2 cm) initially misdiagnosed as hemobilia (123). A case 
mimicking refractory peptic ulcer treated for 8 years was 
also described (76), even hypercalcemia due to elevated 
serum calcitriol in metastatic disease as well (124).
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Risk stratification
The recurrence risk and survival outcomes for dGIST 
are difficult to be determined based solely on the 
histopathological characteristics. Multiple factors have 
been proposed as predictive of survival outcomes, including 
tumor location and size, mitotic rate, kinase mutational 
status, and incidence of tumor rupture. However, tumor 
size and mitotic rate are the two most widely accepted risk 
indicators (125,126).
The Fletcher’s and subsequently the modified National 
Institute of Health classification are the most popular risk 
classifications (95). Miettinen et al., based on the follow-up 
of 140 cases with dGIST, proposed a distinct risk 
stratification of dGIST in which group 1 (<2 cm and 
<5 mitoses) is considered benign, whereas group 6 (>5 cm 
and >5 mitoses) carries an extremely poor prognosis with 
86% mortality (18/21) within 21 months (9). The overall 
mortality in their series was 34%. This classification was 
externally validated by the French Sarcoma group in a 
series with 114 patients (119). The overall doubling time 
for dGIST is 17 months in comparison to leiomyoma 
(231 months). According to the risk group the doubling 
time is 24, 17 and 4 months in low, intermediate and high 
risk dGISTs (115).
Generally, there are contradictory results in the literature 
regarding the prognosis of dGIST in comparison to the 
other localizations. Certain authors reported worse outcome 
in comparison to small bowel and gastric GISTs (43), 
whereas others reported similar prognosis with small 
bowel localization. The more recent, population-based 
study of Guller et al. reported similar survival in gastric, 
duodenal and small bowel GISTs in contrast to colonic 
and extravisceral localizations (127). This finding was 
corroborated after subgroup analysis of two periods (1998–
2004 vs. 2005–2011) thus eliminating a possible cofounding 
factor associated with the implementation of imatinib 
therapy.
Diagnosis
Although it may be straightforward in most cases, certain 
considerations should be kept in mind due to their 
occasionally misleading manifestation (128). Differential 
diagnosis includes adenocarcinoma, endocrine tumors, 
benign tumors and rare entities such as intrabdominal 
fibromatosis (110), ectopic pancreas (129), and Brunner’s 
gland cysts (78).
Because most of dGISTs present with acute bleeding 
or chronic anemia endoscopic evaluation of upper 
gastrointestinal tract should be the first step (101). It allows 
for biopsy and can be also therapeutic. In case of failure, 
transarterial embolization is a method of choice, either as 
definitive hemostasis or as a bridging procedure before 
surgical intervention (39). Occasionally, endoscopy may be 
misleading, especially in small intramural lesions without 
mucosal involvement (ulceration or central depression) or 
located near the papilla Vateri. In such cases of diagnostic 
uncertainty, endoscopic ultrasound (EUS) is an invaluable 
modality. Usually dGISTs appears as hypoechoic and well-
vascularized lesion. Two small series reported a significant 
correlation between the presence of intratumoral vessels on 
contrast-enhanced or color Doppler EUS and the malignant 
potential of dGISTs (130,131). EUS provides a precise 
evaluation of the size, border, layer of origin, echogenicity 
and heterogeneity of the lesions thus facilitating the 
differential diagnosis (lipomas, hemangiomas, ectopic 
pancreas, and cysts) and decision-making process (112). 
Additionally, EUS allows also fine needle or trucut biopsy 
with 100% specificity and 84% sensitivity (92,112,131,132). 
Percutaneous biopsy should be avoided when possible 
because of the risk for tumor spillage and dissemination.
Abdominal US is useful screening tool in the cases with dull 
pain in upper abdomen, but computed tomography (CT) and 
magnetic resonance imaging (MRI) are mandatory to make an 
exact staging and preoperative planning of surgery (107,113). 
On CT dGISTs appear as well-defined, heterogeneously 
enhanced, hypervascular mass with prominent feeding arteries 
and intra- or extramural growth (107,114). In contrast, the 
ectopic pancreas has intraluminal growth and ill-defined 
border with enhancement of the overlying mucosa (129). 
The periampullary pancreatic cancer is usually hypodense 
on arterial phase with concomitant pancreatic duct 
dilatation, periampullary neuroendocrine tumors reveal 
hypervascular enhancement, calcifications, lack of ductal 
obstruction, central necrosis and cystic degeneration, 
whereas sol id periampullary tumors demonstrate 
heterogeneous hypoenhancement in both phases (114). 
Fluorodeoxyglucose positron emission tomography (FDG-
PET) is not routine tool but can be useful to monitor the 
effect from imatinib treatment and follow-up (133,134).
Surgical treatment
The ESMO guideline suggests that tumors under 2 cm has 
low aggressive behaviour and therefore could be followed 
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annually by endoscopic ultrasound, “although an evidence-
based optimal surveillance policy is lacking” (109). In 
contrast to the other localizations, in dGIST there is no 
uniformly adopted surgical strategy because of the low 
incidence, lack of enough experience, and the complex 
anatomy of the duodenum. Therefore, individually tailored 
surgical approach is recommended. In fact, there are 
three main surgical options: pancreatoduodenectomy (PD), 
wedge resection and segmental resection.
PD is indicated in the cases with involvement of major 
duodenal papilla, pancreas or pancreatic duodenal wall and 
is required in 20–40% (101,135). In some cases, it can be 
performed successfully in emergency setting due to life-
threatening bleeding (10,24,111) even with second-stage 
pancreatojejunostomy (17). Tien et al. found that size >5 cm 
and preoperative diagnosis of dGIST were more frequently 
treated by PD (89). In another series, the patients with PD 
had larger tumor size and higher mitotic count (118). A 
recent meta-analysis of seven comparative studies confirmed 
categorically the above-mentioned findings (89).
Imatinib mesylate have played a key role as a neoadjuvant 
therapy in the management of GISTs (21,122). In locally 
advanced disease neoadjuvant imatinib may downstage the 
tumor to allow R0 resection or even an organ preserving 
intervention (11,122,136-138) despite the risk of bleeding (111). 
Ludvigsen et al. reported a successful PD en-block with right 
kidney and suprarenal gland (19). Fukuyama et al. reported 
even avoidance of PD after downstaging neoadjuvant therapy 
with imatinib (67). Recently, successful organ-preserving 
duodenectomies after neoadjuvant therapy in 9 of 10 cases was 
reported (92) similarly to other authors (82).
PD is, however, burdened by significant morbidity 
and longer hospital stay in comparison to local resection, 
probably due to the “soft” pancreas and small caliber of 
pancreatic duct (116,118,119). Moreover, several studies 
reported no significant difference in recurrence rate and 
disease specific survival between limited resection and 
pancreatoduodenectomy (55,97,101,104), which is categorically 
supported from the meta-analysis of Chok et al. (122) 
and the experience of the French Sarcoma Group (119).
R0 resection with 1–2 cm clear margin is sufficient 
treatment and lymph node dissection is not recommended due 
to the low incidence of lymphatic metastases (102). There are 
several options for local resection and surgical reconstruction 
according to the localization of the tumour. The rupture 
of GIST during the surgery should be avoided because 
is associated with nearly 100% risk for recurrence (125). 
Therefore, the good knowledge of anatomy, gentle handling 
of the tissues, and careful dissection of duodenal wall from 
the inferior border of pancreas, meticulous hemostasis and 
knowing of the possible options for duodenal reconstruction 
are mandatory for successful outcomes.
Laparoscopic resection is feasible and safe with reported 
subtotal resection with side-to-side duodenojejunostomy (100) 
and wedge resection (85,139). Tanaka et al. reported eighth 
cases successful segmental resections of duodenojejunal 
junction with side-to-side anastomosis comparable 
with 11 open procedures (140). Some authors reported 
laparoscopically assisted endoscopic submucosal resection 
of 20 mm GIST located in the third portion (57).
There are six reported cases of dGIST localized in first 
and second portion removed by robotic surgery: wedge 
resection (140-142) and segmental resection with side-to-
side duodenojejunostomy (143).
Although in most cases wedge and segmental resections 
could be relatively straightforward, severe complications 
may occur such as acute pancreatitis, pancreatic fistula, 
significant blood loss and anastomotic stenosis (117,118). 
Delayed gastric emptying treating with gastrojejunostomy 
and the fearsome anastomotic failure necessitated secondary 
PD (101) and injury of the mesenteric root managed by 
total enterectomy have been described in the literature (132). 
The pitfalls in segmental resections are associated with 
the superior mesenteric vessels lying on the third portion, 
adjacent pancreas and the common blood supply, necessity 
to preserve ampulla Vateri (117,107).
Conclusions
dGIST is a very rare entity. It may be asymptomatic or may 
involve symptoms of upper GI bleeding and abdominal 
pain at presentation. Because of the misleading clinical 
presentation the differential diagnosis may be difficult. 
Gastrointestinal endoscopy is the most common initial 
diagnostic procedure while abdominal and thoracic CT scan 
are mandatory for accurate oncologic staging and surgical 
planning.
Tumours smaller than 2 cm have a low biological 
aggressiveness and can be followed annually by endoscopic 
ultrasound; the biggest tumors should undergo radical 
surgery (R0) (144). In contrast to the other localizations, 
dGIST have no uniformly adopted surgical strategy because 
of the low incidence, lack of experience, and complex 
anatomy of the duodeno-pancreatic region. Therefore, 
individually tailored surgical approach is recommended. R0 
resection with 1–2 cm clear margin is sufficient treatment 
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and lymph node dissection is not recommended due to 
the low incidence of lymphatic metastases. Tumor rupture 
should be avoided. 
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